Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates
- PMID: 10890360
- DOI: 10.1089/08892220050058407
Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates
Abstract
We generated DNA constructs expressing soluble truncated forms of the envelope of SF162, a neutralization-resistant primary human immunodeficiency virus type 1 isolate, and SF162AV2, a neutralization-susceptible virus derived from SF162 after the deletion of 30 amino acids from the V2 loop. The constructs express the entire gp120 subunit and the extracellular region of the gp41 subunit, with either the presence ("cleaved" forms, designated gp140C) or the absence ("fused" forms, designated gp140F) of the gp120-gp41 cleavage site. Both gp140 forms derived from SF162 and SF162deltaV2 are secreted in the cell medium and are recognized by the oligomer-specific anti-gp41 MAb T4. As is the case for the corresponding virion-associated envelope molecules, the CD4-binding region is occluded within both gp140F and gp140C forms. However, structural differences exist between these two forms. The gp140F proteins are less efficiently recognized than the gp140C proteins by antibodies present in the sera of HIV-infected patients with neutralizing activities against SF162 and SF162AV2. Also, the V3 loop is more exposed on gp140F than gp140C. As is the case for intact virions, on CD4 binding both the gp140F and gp140C proteins undergo conformational changes that result in the exposure of the epitope recognized by MAb 17b, which has been implicated in coreceptor binding. In contrast, during these structural changes the exposure of specific V3 loop epitopes is not increased on either gp140C or gp140F. Taken together, our data indicate that although these gp140 forms differ structurally from the native envelope, their similarities, in particular that of gp140C, outweigh their differences.
Similar articles
-
Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.Virology. 1997 Mar 17;229(2):360-9. doi: 10.1006/viro.1997.8443. Virology. 1997. PMID: 9126249
-
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein.J Virol. 1996 Feb;70(2):753-62. doi: 10.1128/JVI.70.2.753-762.1996. J Virol. 1996. PMID: 8551612 Free PMC article.
-
The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.J Virol. 2001 Jun;75(12):5526-40. doi: 10.1128/JVI.75.12.5526-5540.2001. J Virol. 2001. PMID: 11356960 Free PMC article.
-
Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design.Immunol Lett. 1997 Jun 1;57(1-3):105-12. doi: 10.1016/s0165-2478(97)00043-6. Immunol Lett. 1997. Corrected and republished in: Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0 PMID: 9232434 Corrected and republished. Review.
-
Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".Immunol Lett. 1997 Jul;58(2):125-32. doi: 10.1016/s0165-2478(97)00109-0. Immunol Lett. 1997. PMID: 9271324 Review.
Cited by
-
Novel Therapeutic Approach for Inhibition of HIV-1 Using Cell-Penetrating Peptide and Bacterial Toxins.J AIDS Clin Res. 2017 Oct;8(10):737. doi: 10.4172/2155-6113.1000737. Epub 2017 Oct 23. J AIDS Clin Res. 2017. PMID: 29226013 Free PMC article.
-
Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.Virology. 2007 Sep 30;366(2):433-45. doi: 10.1016/j.virol.2007.05.020. Epub 2007 Jun 8. Virology. 2007. PMID: 17560621 Free PMC article.
-
Selective use of primate CD4 receptors by HIV-1.PLoS Biol. 2019 Jun 10;17(6):e3000304. doi: 10.1371/journal.pbio.3000304. eCollection 2019 Jun. PLoS Biol. 2019. PMID: 31181085 Free PMC article.
-
Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.J Virol. 2008 Jun;82(12):5912-21. doi: 10.1128/JVI.00389-08. Epub 2008 Apr 9. J Virol. 2008. PMID: 18400850 Free PMC article.
-
Highly potent chimeric inhibitors targeting two steps of HIV cell entry.J Biol Chem. 2011 Aug 12;286(32):28370-81. doi: 10.1074/jbc.M111.234799. Epub 2011 Jun 9. J Biol Chem. 2011. PMID: 21659523 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials